Abstract

Differential Expression of miR-589-5p, miR-569 and c-Fos gene in Oral Squamous Cell Carcinoma

Highlights

  • Oral cancer is a group of malignant neoplasms developing on the lip or oral cavity, in which more than 95% of all cancers are oral squamous cell carcinomas (OSCCs) (Awan et al, 2016)

  • RESULTS miR-589-5p and miR-569 Expression Were Downregulated in OSCC: The expression patterns of miR589-5p and miR-569 in 30 paired OSCC tissues and adjacent normal oral tissues were evaluated by Reverse Transcription and Quantitative real-time PCR (RT-qPCR) analysis

  • C-Fos gene Expression Was Upregulated in OSCC: In this study, the expression of cFos as a potential target for miR-589-5p and miR-569 was evaluated using RTqPCR analysis in 30 paired OSCC tissues and adjacent normal oral tissues

Read more

Summary

Introduction

Oral cancer is a group of malignant neoplasms developing on the lip or oral cavity, in which more than 95% of all cancers are oral squamous cell carcinomas (OSCCs) (Awan et al, 2016). OSCC is the most prevalent cancer among the Head and Neck Squamous cell carcinomas (HNSCC) group (48% of cases) (Irani, 2020) and the sixth most common cancer in the world (Rivera, 2015; Borse et al, 2020). It is crucial to keep finding new approaches for early oral cancer diagnosis, especially in high-risk communities (Awan et al, 2016; Irani, 2020). This study aimed to investigate the changes in expression levels of miR-589-5p, miR-569, and c-Fos (as a target gene) in tumor and adjacent normal tissues from OSCC patients. Results: c-Fos expression was significantly increased, while miR-589-5p and miR-569 gene expressions were decreased in tumor tissues compared to normal tissues. Conclusion: miR-589-5p may serve as a potent diagnostic and prognostic biomarkers for OSCC patients and be a potential approach to early diagnosis or prognosis of OSCC in the future. c-Fos overexpression may have a role in OSCC progression and necrosis

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call